Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARV-766 |
| Synonyms | |
| Therapy Description |
ARV-766 is a proteolysis-targeted chimera (PROTAC) that induces degradation of wild-type androgen receptor (AR) and AR ligand-binding domain mutants, which potentially results in antitumor activity (J Clin Oncol 2024 42:16_suppl, 5011). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARV-766 | ARV 766|ARV766|Luxdegalutamide|JSB462 | Hormone - Anti-androgens 57 | ARV-766 is a proteolysis-targeted chimera (PROTAC) that induces degradation of wild-type androgen receptor (AR) and AR ligand-binding domain mutants, which potentially results in antitumor activity (J Clin Oncol 2024 42:16_suppl, 5011). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|